Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FABP4 | P15090 | 1/20 | 0.37 |
| ▸ | FABP5 | Q01469 | 1/20 | 0.37 |
| ▸ | BCHE | P06276 | 4/20 | 0.36 |
| ▸ | ACHE | P22303 | 4/20 | 0.36 |
| ▸ | GLRA1 | P23415 | 1/20 | 0.35 |
| ▸ | LPAR1 | Q92633 | 1/20 | 0.35 |
| ▸ | RXRA | P19793 | 1/20 | 0.35 |
| ▸ | MEN1 | O00255 | 2/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.34 |
| ▸ | NPC1 | O15118 | 1/20 | 0.34 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.34 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.34 |
| ▸ | CFD | P00746 | 1/20 | 0.34 |
| ▸ | F11 | P03951 | 1/20 | 0.34 |
| ▸ | TPSB2 | P20231 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15375542 | 0.89 | FABP4 (0.48) | FABP4FABP5BCHEACHEGLRA1 | |
| SCHEMBL15375554 | 0.87 | FABP4 (0.44) | FABP4FABP5MEN1KMT2AKDM4E | |
| SCHEMBL15402604 | 0.87 | BCHE (0.38) | FABP4FABP5BCHEACHEGLRA1 | |
| SCHEMBL15375348 | 0.86 | TSHR (0.37) | BCHEACHELPAR1KDM4EALDH1A1 | |
| SCHEMBL15401766 | 0.86 | BCHE (0.42) | FABP4FABP5BCHEACHEMEN1 | |
| SCHEMBL15375608 | 0.83 | RXRA (0.46) | RXRANPC1KDM4E | |
| SCHEMBL15401949 | 0.80 | PTGDR2 (0.44) | FABP4FABP5LPAR1MEN1KMT2A | |
| SCHEMBL15375400 | 0.80 | FABP4 (0.44) | FABP4FABP5GLRA1MEN1KMT2A | |
| SCHEMBL1539382 | 0.80 | NISCH (0.36) | FABP4FABP5BCHEACHEGLRA1 | |
| SCHEMBL15375398 | 0.80 | ACHE (0.34) | BCHEACHERXRAMEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2682382-B1 | Method for Producing Phenylacetamide Compound | SUMITOMO CHEMICAL CO (JP) | 2016-11-23 | — | — | EP | disclosed |
| EP-2662352-B1 | Method for Producing Phenylacetamide Compound | SUMITOMO CHEMICAL CO (JP) | 2016-11-09 | — | — | EP | disclosed |
| CN-103588657-B | The manufacture method of phenylacetyl amines | 住友化学株式会社 | 2016-06-22 | — | — | CN | disclosed |
| EP-2397459-B1 | METHOD FOR PRODUCING PHENYLACETAMIDE COMPOUND | SUMITOMO CHEMICAL CO (JP) | 2015-12-16 | — | — | EP | disclosed |
| CN-103641731-B | The manufacture method of phenylacetyl amine compound | SUMITOMO CHEMICAL CO., LTD. (JP) | 2015-10-28 | — | — | CN | disclosed |
| CN-103588657-A | Method for producing phenylacetamide compound | SUMITOMO CHEMICAL CO | 2014-02-19 | — | — | CN | disclosed |
| EP-2682382-A2 | Method for Producing Phenylacetamide Compound | Sumitomo Chemical Company, Limited (JP) | 2014-01-08 | — | — | EP | disclosed |
| US-8624062-B2 | Method for producing phenylacetamide compound | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2014-01-07 | — | — | US | disclosed |
| EP-2662352-A2 | Method for Producing Phenylacetamide Compound | Sumitomo Chemical Company, Limited (JP) | 2013-11-13 | — | — | EP | disclosed |
| EP-2397459-A1 | METHOD FOR PRODUCING PHENYLACETAMIDE COMPOUND | Sumitomo Chemical Company, Limited (JP) | 2011-12-21 | — | — | EP | disclosed |
| US-20110295035-A1 | METHOD FOR PRODUCING PHENYLACETAMIDE COMPOUND | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2011-12-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110295035-A1 | METHOD FOR PRODUCING PHENYLACETAMIDE COMPOUND | MRPL21, AADAC, ARSA | FABP4 4349/4885FABP5 4435/4885BCHE 2680/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.